Skip to main content

Type 2 diabetes and cardiovascular disease

medwireNews

09-25-2023 | Gestational diabetes | News

Gestational diabetes independently linked to increased future mortality risk

Women with a history of gestational diabetes have a significantly increased risk for long-term mortality regardless of whether or not they subsequently developed type 2 diabetes.

09-20-2023 | Latent autoimmune diabetes of adulthood | News

Latent autoimmune diabetes carries mortality and CVD risks comparable to type 2 diabetes

Latent autoimmune diabetes in adults is associated with similar risks for mortality and cardiovascular disease and an increased risk for retinopathy compared with type 2 diabetes.

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

07-07-2023 | Type 2 diabetes | News

New atherothrombotic risk score for type 2 diabetes

The TIMI Risk Score for Atherothrombosis in Diabetes categorises risk of myocardial infarction or stroke in people with type 2 diabetes.

06-22-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

04-24-2023 | Heart failure | News

Prescription NSAID use may trigger heart failure in type 2 diabetes

A case-crossover study supports a link between use of non-steroidal anti-inflammatory drugs and development of heart failure in people with type 2 diabetes.

04-24-2023 | Sulfonylureas | News

Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

03-10-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

02-08-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

12-20-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

12-06-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

12-01-2022 | Semaglutide | News

High-dose semaglutide reduces obesity-linked inflammatory marker

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

11-21-2022 | Cancer | News

Type 2 diabetes linked to advanced stage at cancer diagnosis

Having type 2 diabetes increases a person’s risk for a cancer being already metastatic at the point of diagnosis, shows an EPIC analysis.

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

Human kidney cross section

11-08-2022 | SGLT2 inhibitors | News

Meta-analysis backs SGLT2 inhibitors for kidney disease

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

11-07-2022 | Lipid-lowering medications | News

Pemafibrate disappoints in high-risk type 2 diabetes

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

11-04-2022 | Empagliflozin | News | Article

EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

10-24-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.

Cardiovascular event - symbolic image

10-21-2022 | Cardiovascular disorders | News

Diabetes ‘no longer a CVD risk equivalent’

The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.

10-13-2022 | Anti-hypertensive medications | News

TIME of antihypertensive administration ‘should be shared decision’

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.